Heart Failure
We recommend
Under the Microscope: How is Patient Care for Heart Failure in the Czech Republic in Real Practice?
The journal Vnitřní lékařství recently published the results of a survey conducted among outpatient cardiologists and internists. The aim was to determine the level of diagnosis and treatment of patients with chronic heart failure (CHF) in real-life practice in the Czech Republic, with a special focus on the presence of symptoms in patients who have not yet been diagnosed. We briefly summarize the key findings from this survey.
ACC 2023 Expert Consensus: How to Optimize Diagnosis and Treatment of Heart Failure with Preserved EF LK
Heart failure (HF) remains a significant cause of morbidity and mortality, with the incidence and…
Improving treatment outcomes of HF with preserved ejection fraction according to JACC: What does the success of gliflozins mean for the future?
The Journal of the American College of Cardiology (JACC) recently issued a scientific statement in…
Articles on this topic
Webinar SGLT2i in ESC HF Guidelines vs. Real Practice
Dear Doctor,
Boehringer Ingelheim, in collaboration with the 2nd Department of Internal…
Mechanisms of Cardioprotective Effects of SGLT2 Inhibitors
Inhibitors of sodium-glucose cotransporter 2 (SGLT2i, gliflozins) are a relatively new group…
Basic Cardiovascular Benefits of the Oral Antidiabetic Medication Empagliflozin
Type 2 diabetes mellitus is one of the main risk factors for cardiovascular (CV) diseases.…
Heart Failure in the Light of New ESC Guidelines
Dear Doctor, The Czech Society of Internal Medicine of ČLS JEP invites you to watch the…
Current Recommendations for Using SGLT2 Inhibitors in Patients with Renal or Cardiovascular Risk
Type 2 diabetes mellitus (DM2) is a serious chronic metabolic disease whose prevalence has…
Extension of Expected Lifetime When Treated with Empagliflozin in Patients with Type 2 Diabetes and Cardiovascular Disease
Reduction in expected lifetime is one of the main consequences of type 2 diabetes (T2DM). It…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- Empagliflozin Secures Reimbursement for Heart Failure Treatment
- Empagliflozin will be funded from May for symptomatic heart failure regardless of EF LK value
- Summary of New American Recommendations for Heart Failure Management
- EMA Approved Empagliflozin for the Treatment of Heart Failure Regardless of Left Ventricular Ejection Fraction
- Cardio-renal-metabolic syndrome in context
- The Latest Updates of ESC Recommendations for Heart Failure Treatment
Journal on this topic
Related topic